JP Morgan Chase
CGEM icon

JP Morgan Chase’s Cullinan Oncology CGEM Stock Holding History

JP Morgan Chase’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.21M Sell
282,631
-14,600
-5% -$217K ﹤0.01% 3414
2026
Q1 		$3.99M Buy
297,231
+150,176
+102% +$1.93M ﹤0.01% 3532
2025
Q4 		$1.52M Buy
147,055
+115,187
+361% +$1.04M ﹤0.01% 4311
2025
Q3 		$189K Sell
31,868
-65,201
-67% -$477K ﹤0.01% 5549
2025
Q2 		$731K Buy
97,069
+53,522
+123% +$430K ﹤0.01% 4567
2025
Q1 		$330K Sell
43,547
-154,667
-78% -$1.48M ﹤0.01% 5019
2024
Q4 		$2.41M Buy
198,214
+169,104
+581% +$2.43M ﹤0.01% 4003
2024
Q3 		$487K Buy
29,110
+5,842
+25% +$104K ﹤0.01% 4911
2024
Q2 		$406K Buy
23,268
+3,798
+20% +$80.9K ﹤0.01% 4798
2024
Q1 		$332K Sell
19,470
-5,723
-23% -$88.4K ﹤0.01% 5051
2023
Q4 		$257K Buy
25,193
+879
+4% +$7.79K ﹤0.01% 5228
2023
Q3 		$220K Buy
24,314
+3,635
+18% +$37.9K ﹤0.01% 5015
2023
Q2 		$223K Sell
20,679
-1,564
-7% -$16.6K ﹤0.01% 5014
2023
Q1 		$228K Buy
22,243
+2,858
+15% +$31.5K ﹤0.01% 4986
2022
Q4 		$205K Sell
19,385
-524
-3% -$6.37K ﹤0.01% 5028
2022
Q3 		$256K Buy
19,909
+1,914
+11% +$25.8K ﹤0.01% 4826
2022
Q2 		$231K Sell
17,995
-6,177
-26% -$70K ﹤0.01% 5000
2022
Q1 		$253K Buy
24,172
+4,115
+21% +$55.6K ﹤0.01% 5066
2021
Q4 		$309K Buy
20,057
+4,918
+32% +$98.1K ﹤0.01% 5116
2021
Q3 		$341K Buy
15,139
+7,015
+86% +$188K ﹤0.01% 4938
2021
Q2 		$209K Sell
8,124
-30,077
-79% -$925K ﹤0.01% 5225
2021
Q1 		$1.59M Buy
+38,201
New +$1.55M ﹤0.01% 3883

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

JP Morgan Chase's CGEM Position: Q2 2026 in Review

JP Morgan Chase reduced its Cullinan Oncology (CGEM) stake by 4.9% in Q2 2026, selling an estimated $217K and leaving 282,631 shares worth $5.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3414.

JP Morgan Chase first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • JP Morgan Chase held 282,631 shares of Cullinan Oncology worth $5.21M as of Q2 2026.
  • JP Morgan Chase sold 14,600 Cullinan Oncology shares in Q2 2026, an estimated $217K.
  • Cullinan Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3414 holding.
  • JP Morgan Chase first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.